Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank:DB00472_nanopub.RAapTTQVKF9dqgClDBfPYgYanlZxhdANouLgZpE3KobD4#assertion>. }
Showing items 1 to 29 of
29
with 100 items per page.
- drugbank:DB00472 type drugbank_vocabulary:Drug assertion.
- drugbank:DB00472 label "Fluoxetine [drugbank:DB00472]" assertion.
- drugbank:DB00472 seeAlso DB00472 assertion.
- drugbank:DB00472 seeAlso fluoxetine.html assertion.
- drugbank:DB00472 seeAlso fluoxetine.htm assertion.
- drugbank:DB00472 identifier "drugbank:DB00472" assertion.
- drugbank:DB00472 description "Fluoxetine hydrochloride is the first agent of the class of antidepressants known as selective serotonin-reuptake inhibitors (SSRIs). Fluoxetine is a racemic mixture of the R- and S- enantiomers and are of equivalent pharmacologic activity. Despite distinct structural differences between compounds in this class, SSRIs possess similar pharmacological activity. As with other antidepressant agents, several weeks of therapy may be required before a clinical effect is seen. SSRIs are potent inhibitors of neuronal serotonin reuptake. They have little to no effect on norepinephrine or dopamine reuptake and do not antagonize α- or β-adrenergic, dopamine D<sub>2</sub> or histamine H<sub>1</sub> receptors. During acute use, SSRIs block serotonin reuptake and increase serotonin stimulation of somatodendritic 5-HT<sub>1A</sub> and terminal autoreceptors. Chronic use leads to desensitization of somatodendritic 5-HT<sub>1A</sub> and terminal autoreceptors. The overall clinical effect of increased mood and decreased anxiety is thought to be due to adaptive changes in neuronal function that leads to enhanced serotonergic neurotransmission. Side effects include dry mouth, nausea, dizziness, drowsiness, sexual dysfunction and headache. Side effects generally occur within the first two weeks of therapy and are usually less severe and frequent than those observed with tricyclic antidepressants. Fluoxetine may be used to treat major depressive disorder (MDD), moderate to severe bulimia nervosa, obsessive-compulsive disorder (OCD), premenstrual dysphoric disorder (PMDD), panic disorder with or without agoraphobia, and in combination with olanzapine for treatment-resistant or bipolar I depression. Fluoxetine is the most anorexic and stimulating SSRI." assertion.
- drugbank:DB00472 title "Fluoxetine" assertion.
- drugbank:DB00472 bio2rdf_vocabulary:identifier "DB00472" assertion.
- drugbank:DB00472 bio2rdf_vocabulary:namespace "drugbank" assertion.
- drugbank:DB00472 bio2rdf_vocabulary:uri "http://bio2rdf.org/drugbank:DB00472" assertion.
- drugbank:DB00472 bio2rdf_vocabulary:x-identifiers.org DB00472 assertion.
- drugbank:DB00472 drugbank_vocabulary:drugbank-id "APRD00530" assertion.
- drugbank:DB00472 drugbank_vocabulary:drugbank-id "DB00472" assertion.
- drugbank:DB00472 drugbank_vocabulary:x-cas cas:54910-89-3 assertion.
- drugbank:DB00472 drugbank_vocabulary:x-chemspider chemspider:3269 assertion.
- drugbank:DB00472 drugbank_vocabulary:x-pubchemcompound pubchem.compound:3386 assertion.
- drugbank:DB00472 drugbank_vocabulary:x-pubchemsubstance pubchem.substance:46507902 assertion.
- drugbank:DB00472 drugbank_vocabulary:x-ahfs ahfs:28:16.04.20 assertion.
- drugbank:DB00472 drugbank_vocabulary:x-atc atc:N06AB03 assertion.
- drugbank:DB00472 drugbank_vocabulary:x-chebi chebi:5118 assertion.
- drugbank:DB00472 drugbank_vocabulary:x-dpd dpd:2242124 assertion.
- drugbank:DB00472 drugbank_vocabulary:x-kegg kegg:D00823 assertion.
- drugbank:DB00472 drugbank_vocabulary:x-pharmgkb pharmgkb:PA449673 assertion.
- drugbank:DB00472 drugbank_vocabulary:x-wikipedia wikipedia:Fluoxetine assertion.
- drugbank:DB00472 drugbank_vocabulary:x-bindingdb bindingdb:30130 assertion.
- drugbank:DB00472 drugbank_vocabulary:x-ndc ndc:63304-632-30 assertion.
- drugbank:DB00472 drugbank_vocabulary:x-gtp gtp:203 assertion.
- drugbank:DB00472 drugbank_vocabulary:x-iuphar iuphar:203 assertion.